Meyka Pro banner
Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd. (2179.HK) Stock Competitors & Peer Comparison

See (2179.HK) competitors and their performances in Stock Market.

2179.HKHKSE
HealthcareBiotechnology
HK$5.04
HK$0.00(0.00%)
Hong Kong Market is Open · 14:21

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2179.HKHK$5.05+1.00%2.7B-3.42-HK$1.48N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$185.60-2.73%250.3B83.91HK$2.21N/A
1801.HKHK$88.95-5.57%154.9B163.57HK$0.54N/A
2269.HKHK$36.98-5.95%153.2B28.94HK$1.28N/A
6990.HKHK$486.40-6.91%113.4B-241.15-HK$2.02N/A
9926.HKHK$88.35-13.21%81.3B-65.86-HK$1.34N/A
3347.HKHK$36.70-6.47%44.5B37.56HK$0.98+0.39%
6821.HKHK$117.20-8.94%42.3B38.43HK$3.05+1.28%
1530.HKHK$16.15-9.83%40.4B4.21HK$3.84+1.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2179.HK vs 4332.HK Comparison July 2026

2179.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2179.HK stands at 2.7B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2179.HK is priced at HK$5.05, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2179.HK currently has a P/E ratio of -3.42, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2179.HK's ROE is -1.37%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2179.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2179.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions